Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Riffat Qureshi

Psychiatry Orlando, FL Medical Doctor

NPI 1134114416 CMS profile 452521

1800 Mercy Dr, Orlando, FL 32808

Open in the dashboard

General payments

$4,374

189 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Riffat Qureshi of Orlando, FL is reported in the CMS Open Payments database as having received $4,374 across 189 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,104 48
2024 General $850 39
2023 General $544 28
2022 General $472 23
2021 General $489 23
2020 General $121 1
2019 General $794 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Riffat Qureshi
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Riffat Qureshi were reported at $1,104. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Riffat Qureshi Psychiatry median Middle half National median
2019 $794 $184 $59–$605 $163
2020 $121 $119 $36–$372 $114
2021 $489 $143 $43–$576 $132
2022 $472 $153 $50–$590 $149
2023 $544 $170 $56–$651 $160
2024 $850 $179 $57–$673 $164
2025 $1,104 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $767 47 payments
  2. Vanda Pharmaceuticals Inc. $529 18 payments
  3. ITI, Inc. $469 21 payments
  4. Otsuka America Pharmaceutical, Inc. $455 20 payments
  5. Neurocrine Biosciences, Inc. $433 14 payments
  6. Sunovion Pharmaceuticals Inc. $343 8 payments
  7. Janssen Pharmaceuticals, Inc $327 12 payments
  8. Lundbeck LLC $176 8 payments
  9. Allergan Inc. $162 4 payments
  10. E.R. Squibb & Sons, L.L.C. $146 7 payments
  11. Other $568 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,346 188 payments
  2. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $566 35 payments
  2. FANAPT $529 18 payments
  3. HETLIOZ $414 14 payments
  4. CAPLYTA $393 18 payments
  5. VRAYLAR Neuroscience $363 16 payments
  6. LATUDA $343 8 payments
  7. SPRAVATO $289 9 payments
  8. ABILIFY MAINTENA $288 12 payments
  9. INGREZZA $280 11 payments
  10. REXULTI $253 11 payments
  11. Other $1,638 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,452

Median for Psychiatry: 574

Drug cost

$42,337

Median for Psychiatry: $27,624

Branded share of claims

9.8%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 12 $19,794
Vilazodone Hcl Generic 29 $3,740
Asenapine Maleate Generic 19 $2,654
Oxcarbazepine Generic 47 $2,410
Quetiapine Fumarate Generic 106 $1,953
Buspirone Hcl Generic 106 $1,310
Aripiprazole Generic 47 $1,104
Ziprasidone Hcl Generic 22 $942
Bupropion Xl Bupropion Hcl Brand 76 $927
Lurasidone Hcl Generic 27 $876

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$12,886

Medicare's payments for the services billed

Medicare patients

44

Average age 61

Services billed

182

24 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 43%
Alzheimer's or dementia 30%
Ischemic heart disease 27%
COPD 27%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $158
$158 12 —
INGREZZA
  • Neurocrine Biosciences, Inc. $139
$139 — —
CAPLYTA
  • ITI, Inc. $114
$114 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $69
  • Lundbeck LLC $44
$113 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

189 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record